<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gordon, Debra</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Price, Matthew J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">High-Dose Clopidogrel in Patients with High Residual Reactivity: Results from the GRAVITAS Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">Doubling the dose of clopidogrel in patients with high residual platelet activity after percutaneous intervention has no significant effect on cardiovascular outcomes, according to the neutral results of the Gauging Responsiveness with A VerifyNow Assay—Impact on Thrombosis And Safety [GRAVITAS; NCT00645918] trial.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>